SCHEMBL3744930

SCHEMBL3744930

Cc1cccc(NCC2=CC[C@H](c3cc(F)c(F)cc3F)[C@@H](N)C2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 10/20 0.48
DPP8 Q6V1X1 1/20 0.48
DPP9 Q86TI2 1/20 0.48
MAPT P10636 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.36
ALDH1A1 P00352 1/20 0.33
DRD4 P21917 1/20 0.33
DPP7 Q9UHL4 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3744934 1.00 DPP4 (0.48) DPP4DPP8DPP9MAPTCYP1A2
SCHEMBL3744937 1.00 DPP4 (0.48) DPP4DPP8DPP9MAPTCYP1A2
SCHEMBL3745169 0.89 DPP4 (0.49) DPP4DPP8DPP9MAPTHPGD
SCHEMBL3745161 0.89 DPP4 (0.49) DPP4DPP8DPP9MAPTHPGD
SCHEMBL3745166 0.89 DPP4 (0.49) DPP4DPP8DPP9MAPTHPGD
SCHEMBL3750724 0.88 DPP4 (0.49) DPP4DPP8DPP9DPP7
SCHEMBL3750717 0.88 DPP4 (0.49) DPP4DPP8DPP9DPP7
SCHEMBL3750722 0.88 DPP4 (0.49) DPP4DPP8DPP9DPP7
SCHEMBL3745307 0.87 DPP4 (0.48) DPP4DPP8DPP9CYP1A2CYP2C9
SCHEMBL3745301 0.87 DPP4 (0.48) DPP4DPP8DPP9CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919854-B1 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) ABBVIE INC (US) 2013-09-18 EP claimed
US-20070049596-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBVIE INC. 2007-03-01 US claimed
EP-1919854-B1 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) ABBVIE INC (US) 2013-09-18 EP disclosed
US-7834012-B2 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-20070049596-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBVIE INC. 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049596-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) DPP4, DPP3, DPP7 DPP4 1/4885DPP8 5/4885DPP9 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.